Safety and Pharmacology Study of BMS-866949

Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-866949 in Healthy Subjects

The main purpose of this study is to determine whether multiple doses.of BMS-886949 are safe and tolerable

Inclusion Criteria:

• Panels 1-6: Healthy Male Subjects
• Panel 7: Females
• Ages 21 to 55, inclusive
• Body Mass Index (BMI) of 18 to 32 kg/m², inclusive
• Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations

Exclusion Criteria:

• History of glaucoma or a confirmed intraocular pressure indicative of glaucoma at screening. (Normal IOP <21 mmHg)
• History or family history of psychiatric disorder
• Current treatment with prescription medication
• Exposure to any investigational drug or placebo within 12 weeks of study drug administration